Comparative Production Analysis of Three Phlebovirus Nucleoproteins under Denaturing or Non-Denaturing Conditions for Crystallographic Studies by Lantez, Violaine et al.
Comparative Production Analysis of Three Phlebovirus
Nucleoproteins under Denaturing or Non-Denaturing
Conditions for Crystallographic Studies
Violaine Lantez
1, Karen Dalle
1,R e ´mi Charrel
2,C e ´cile Baronti
2, Bruno Canard
1, Bruno Coutard
1*
1Architecture et Fonction des Macromole ´cules Biologiques, UMR 6098 Centre National de la Recherche Scientifique, Universite ´ de la Me ´diterrane ´e and Universite ´ de
Provence, Marseille, France, 2Unite ´ des Virus Emergents, UMR 190, Aix-Marseille Universite ´ and Institut de Recherche pour le De ´veloppement, Marseille, France
Abstract
Nucleoproteins (NPs) encapsidate the Phlebovirus genomic (-)RNA. Upon recombinant expression, NPs tend to form
heterogeneous oligomers impeding characterization of the encapsidation process through crystallographic studies. To
overcome this problem, we set up a standard protocol in which production under both non-denaturing and denaturing/
refolding conditions can be investigated and compared. The protocol was applied for three phlebovirus NPs, allowing an
optimized production strategy for each of them. Remarkably, the Rift Valley fever virus NP was purified as a trimer under
native conditions and yielded protein crystals whereas the refolded version could be purified as a dimer. Yields of trimeric
Toscana virus NP were higher from denaturing than from native condition and lead to crystals. The production of Sandfly
Fever Sicilian virus NP failed in both protocols. The comparative protocols described here should help in rationally choosing
between denaturing or non-denaturing conditions, which would finally result in the most appropriate and relevant
oligomerized protein species. The structure of the Rift Valley fever virus NP has been recently published using a refolded
monomeric protein and we believe that the process we devised will contribute to shed light in the genome encapsidation
process, a key stage in the viral life cycle.
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Introduction
The genus Phlebovirus belongs to the Bunyaviridae family that
includes four others genera, namely Hantavirus, Nairovirus, Orthobu-
nyavirus, and Tospovirus. Phleboviruses have a worldwide distribu-
tion and are associated with a wide variety of arthropods (sandflies,
mosquitoes, ticks). Rift Valley fever virus (RVFV), the prototype
species of the genus, is endemic in Africa, where it is zoonotic,
infecting mainly sheep, and causing severe disease with high rates
death through abortion in sheep. During these outbreaks, RVFV
can pass to human either directly via abortion products or via
mosquito transmission, leading occasionally to potentially fatal
meningoencephalitis and/or haemorrhagic fevers. Recent out-
breaks occurred in the horn of Africa [1–2] and the virus also
spread into the Arabic peninsula [3]. Outbreaks are directly
correlated to rainfalls in these regions and thus, climate and
vegetation data may be used to predict areas and periods at risk
[4]. In the Mediterranean basin phleboviruses other than RVFV
are well established, and seroprevalence can in some regions reach
20% in man [5]. Phleboviruses are mainly represented by Sandfly
Fever Sicilian virus (SFSV), Sandfly Fever Naples virus (SFNV),
Toscana virus (TOSV) and viruses more or less distantly related to
SFNV and SFSV [6,7,8]. These phleboviruses are transmitted by
phlebotomine flies in regions where the latter circulate. SFN- and
SFS-like viruses can cause mild febrile illnesses (sometimes
paucisymptomatic) which are likely to be largely underestimated
due to the lack of diagnosis, little awareness among health
professionals. Toscana virus is in the top three viral etiologies of
aseptic meningitis in Italy, Spain and France [9–10]. In this
respect, phleboviruses are representative of Bunyaviridae. Among
the viral world, this family was the major responsible for emerging
infectious diseases (EIDs) events between 1940 and 2004 (figure 1,
data extracted from [11]), even more represented than the
Flaviviridae. Therefore, efforts should be brought not only in
diagnosis but also in the understanding of the viral cycle to
emphasize antiviral research against these viruses.
Phleboviruses, and in general members of the family Bunyavir-
idae, are enveloped spherical viruses of icosahedral geometry [12–
13] with an 80–120 nm long diameter. Their genome is made of
three segments [14]. Among these segments, two are single
negative stranded (M and L) whereas the third one (S) can adopt
an ambisense strategy of expression [15]. The L fragment is
encoding the L protein that is carrying the RNA dependent RNA
polymerase activity involved in the primary and secondary
transcription generating mRNA and replicative intermediates,
respectively. In complement, L is also presumably carrying the cap
snatching activity required in the viral mRNA capping [16]. The
M segment is coding for the glycoprotein precursor that is cleaved
by host proteases in two structural domains GC and GN [17]. The
S fragment can code for the non structural protein NSs as well as
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acids protein (for Rift Valley fever virus) that can bind to genomic
RNA and replicative intermediates to form ribonucleoproteic
complexes (RNP) of circular appearance [18–19]. The NP
oligomerization and its RNA binding properties have not been
extensively described until recently. NPs can dimerize with the
involvement of their N-terminal domain and this NP-NP
interaction does not depend on the presence of RNA [20–21].
To date, no physiological multimeric stage over dimerization has
been clearly identified. Biophysical and structural studies of the NP
alone would therefore provide insights into RNP formation
process. For such studies, it would be beneficial to purify
homogeneous preparations of monomeric nucleoprotein, or at
least, NP assemblies of tractable, defined multimerization status.
Many previous studies reported the expression and purification
of nucleoproteins for various applications. The NP protein of
RVFV can be expressed in insect cells using the recombinant
baculovirus technology, but the protein forms a high molecular
weight RNP complex, as shown by size exclusion chromatography
[22]. The NP proteins have already been produced in E. coli for
ELISA experiments. The proteins were purified under denaturing
conditions [23], with a large N-terminal non cleavable tag [24], or
the purification procedure was stopped after the first affinity
purification step [25]. Only recently, RVFV NP was purified by
refolding the recombinant protein while the natively produced
protein was considered as heterogeneous. The refolded protein
lead to the first crystal structure determination of the phlebovirus
NP [26]. In solution, the refolded protein behaved as a monomer
and the NP crystallized as a dimer that was thought to occur
naturally. Nevertheless, in this study, the role and the presence of
the dimer in the NP oligomeric form observed by electron
microscopy remained unclear.
In order to further understand the structural properties of
phlebovirus NP, it is necessary to set up a process that would lead
to the production of protein oligomers pure and homogeneous in
size, as previously performed for the rabies NP [27]. Additionally,
the process would include a tag removal to improve crystallization.
To that aim, and based on the existing results, we decided to
evaluate two strategies relying on bacterial recombinant expression
for the production of several phlebovirus NP protein suitable for
structural studies. These strategies already met success in large
scale structural genomics projects. Firstly, the screening of N-
terminal tags can drastically improve soluble expression [28–29].
Secondly, when proteins are reluctant to soluble expression, they
can be expressed as inclusion bodies (IB) before being refolded in
non-denaturing conditions [30–31]. In this study, both strategies
will be performed in parallel, even if proteins can be expressed in
the soluble fraction, in order to provide comparative data suitable
to design optimized production protocols for NP proteins. In
addition to the production of NPs suitable for structural studies,
these data may highlight trends in the larger field of recombinant
protein expression.
Figure 1. Number of emerging infectious diseases (EIDs) related to RNA viruses (1940–2004) period [11]. Virus families are organised by
genome structure: negative single strand RNA (ss RNA(-)) positive single strand RNA (ss RNA(+)), and double strand RNA (ds RNA).
doi:10.1371/journal.pntd.0000936.g001
Author Summary
Phleboviruses have a worldwide distribution and are
usually represented by their prototype Rift Valley fever
virus that can have a great impact on health and economy
in Africa. The genome of phleboviruses is a segmented
negative strand RNA that is encapsidated by the nucleo-
protein. The structure of the monomeric nucleoprotein has
been recently published but it’s not sufficient to decipher
a convincing mechanism for the nucleoprotein oligomer-
ization. In order to understand this key step in the virus life
cycle, the purification of oligomers homogeneous in size
would be a key step to launch structural studies. To that
aim, a procedure relying on recombinant protein produc-
tion in both denaturing and non-denaturing conditions
was applied to three phlebovirus nucleoproteins. Although
the best production pipeline differs for each protein, pure
and homogeneous solutions of Rift Valley fever virus and
Toscana virus nucleoproteins were successfully obtained.
Both proteins, behaving as apparent trimers in solution,
lead to protein crystallization, a starting point to under-
stand the genome encapsidation through structural
studies.
Production of Phlebovirus Nucleoproteins
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Cloning and protein expression
cDNA corresponding to the three Nucleoproteins (NP) of Rift
Valley fever virus (RVFV, strain Smithburn DQ380157.1),
Sandfly Fever Sicilian virus (SFSV, strain J04418.1) and Toscana
virus (TOSV, strain AR2005) were amplified using two Polymer-
ase Chain Reactions (PCR). A first amplification was performed
using i) a forward primer carrying the coding sequence of the
Tobacco Etch Virus (TEV) protease cleavage site followed by the
21 nucleotides of the NP sequences (59 GAAAACCTGTACTTC-
CAGGGT-21 nt 39) and ii) a reverse primer carrying attB2
sequence for cloning by recombination, two stop codons and the
21 nucleotides long reverse complement sequence of the NP (59
GGGGACCACTTTGTACAAGAAAGCTGGGTC TTATTA -
21 nt reverse complement 39). A second PCR was done on the first
PCR product using the same reverse primer and a universal
forward primer carrying the attB1 sequence as well as two
additional nucleotides (TA) for the coding frame, and a sequence
hybridizing the TEV protease cleavage site (59 GGGGA-
CAAGTTTGTACAAAAAAGCAGGCT TA GAAAACCTG-
TACTTCCAGGGT 39). This second PCR products were cloned
into the pDonR201 plasmid by recombination (Gateway, Invitro-
gen). The resulting entry clones were sequenced. The entry clones
were then used as templates to clone the NP into two expression
plasmids (see figure 2): pDest17 (Invitrogen), that allows the
expression of the NP in fusion with a N-terminal Hexahistidine
(6His) tag, removable with the inserted TEV protease cleavage site
and pETG20A (kindly provided by Dr A. Geerlof) that allows the
expression of the NP in fusion with a removable Thioredoxin-
Hexahistidine (TRX-6His) tag. The resulting expression plasmids
were transformed in C41 (DE3) E. coli strain (Avidis SA) carrying
the pRARE plasmid (Novagen). For each construct, one liter of
Terrific Broth (Athena Enzymes) containing 100 mg/l of ampi-
cillin and 34 mg/l of chloramphenicol was inoculated with 30 ml
of an overnight pre-culture. The bacteria were grown at 37uCu p
to OD600 nm reached 0.8. Recombinant protein expression was
then induced by adding 0.5 mM isopropyl b-D-1-thiogalactopyr-
anoside (IPTG) and the culture temperature was dropped to 17uC
for 16 hours. Cells were harvested by centrifugation at 4 000 g, 10
minutes. Cell pellets were then resuspended in 50 mM Tris buffer,
300 mM NaCl, 10 mM imidazole, 0.1% Triton, and 5% glycerol
(pH 8.0). Lysozyme (0.25 mg/ml), phenylmethylsulfonyl fluoride
(1 mM), DNase I (2 mg/ml), and EDTA-free protease cocktail
(Roche) were added before performing a sonication step. The
lysates were centrifuged at 12 000 g for 45 minutes. For both 6His
and TRX-6His constructs, the supernatants were collected for the
purification procedure in non-denaturing conditions, whereas for
the 6His constructs, the pellets were used for the purification
process in denaturing conditions, as described in figure 2.
Figure 2. Production process with in-parallel denaturing and non-denaturing procedures applied to the three nucleoproteins.
doi:10.1371/journal.pntd.0000936.g002
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The recombinant soluble proteins were purified from the
supernatant previously recovered using the Akta Xpress fast
purification liquid chromatography system (GE Healthcare) as
follows. The first purification step (immobilized metal affinity
chromatography) was performed on a 5-ml His prep column (GE
Healthcare). The clarified bacterial lysates were loaded at 5 ml/
min. The columns were then washed with a washing buffer
(50 mM Tris, 300 mM NaCl and 50 mM imidazole pH 8.0) and
the proteins were eluted with 50 mM Tris, 300 mM NaCl and
500 mM imidazole pH 8.0. The elution fraction (15 ml) was then
dialyzed against a buffer compatible with the TEV protease
activity (Hepes 10 mM, NaCl 300 mM, pH 7.5). 6His tagged
TEV protease mutant selected for optimized expression [32] was
added to the protein samples in a 1/20 (w/w) ratio and cleavage
was performed 16 hours a `4 uC. The tag removal efficacy was
evaluated on a Coomassie blue stained SDS Page gel by ImageJ
software and was calculated on the band surface and intensity of
the full lengths TRX-6His fusions: [100-(IACSAC/IBCSBC)x100]%
where I is the intensity of the band, S is the surface, ‘‘AC’’ is ‘‘After
Cleavage’’ and ‘‘BC’’ is ‘‘Before Cleavage’’. After cleavage, the
solution was loaded on a 5-ml His prep column and the cleaved
proteins were collected in the flow through, whereas 6His-TEV
protease, TRX-6His tag and not cleaved fusions were retained
onto the column. The cleaved proteins were further purified by a
Size Exclusion Chromatography (SEC) in 10 mM Hepes,
300 mM NaCl, pH 7.5 using a 16/60 Superdex 75 (GE
Healthcare). The SEC was calibrated using the LMW and
HMW calibration kits (GE Healthcare) in order to convert elution
volumes in Molecular Weights. The purity of the samples was
checked on Coomassie blue stained SDS Page gels. The fraction of
the low molecular weight oligomer of NP (LMWNP) amenable to
protein crystallization was defined as: (PALMWNP/PAALLx100)%
where PA is the ‘‘peak area’’ of the SEC chromatogram at
OD280 nm. The identity of the recombinant proteins were
confirmed by matrix-assisted laser desorption ionization-time of
flight mass (MALDI-TOF, Bruker Autoflex, Bruker Daltonics,)
spectrometry after trypsin digestion. Finally, the oligomerization
was also assessed on Coomassie blue stained SDS Page gels, with
an upstream treatment with glutaraldehyde, as previously
described [20]. Briefly, different collected fractions were incubated
30 minutes at room temperature with glutaraldehyde at a 0.05%
concentration. The samples were then denatured 5 minutes at
95uC in SDS Page sample buffer (100 mM Tris pH 6.8, 25%
glycerol, 10% sodium dodecyl sulfate, 5 mM b-mercaptoethanol,
bromophenol blue) prior electrophoresis on SDS Page gels.
Purification under denaturing conditions
The pellets obtained from the centrifuged cell lysates were
washed twice to purify the inclusion bodies. The pellets were
resuspended in a first washing buffer (50 mM Tris, 25 mM
Imidazole, 300 mM NaCl, 1 M urea, 0.1% Triton, pH 8) and
centrifuged at 12 000 g during 30 minutes. The supernatant was
removed and the new pellets were resuspended in a second washing
buffer (50 mM Tris, 25 mM Imidazole, 300 mM NaCl, 1 M urea,
pH 8). After a second centrifugation step (12 000 g, 30 minutes),
inclusion bodies recovered from the pellets were solubilized in a
denaturing buffer (50 mM Tris, 300 mM NaCl, 25 mM Imidazole,
8 M Guanidium, pH 8). The purity of the recombinant proteins
was assessed on Coomassie blue stained SDS Page gels and their
quantity was evaluated at OD280 nm. Denaturing proteins were
concentrated up to about 10 mg/ml and diluted 1/20 (v/v) in a
refolding buffer (50 mM Sodium acetate, 100 mM KCl, 10 mM b-
mercaptoethanol, pH 4.5) at 4uC overnight. The refolding volume
did not exceed 60 ml (30 mg of the protein) in order to have protein
quantities and volumes compatible withthe downstreamprocedure.
The observed aggregates after refolding were removed by
centrifugation (10 000 g, 15 minutes) and the solution was further
clarified using filtration on 0.22 mm filters. A preliminary refolding
efficacy was calculated as follow: (1006[NP]Sol/[NP]BR)%, where
‘‘[NP]Sol’’ is the NP concentration in the soluble fraction after
refolding and [NP]BR is the NP concentration before refolding
(0.5 mg/ml). The refolded proteins were then concentrated on
Amicon Ultra 10 K (Milipore) up to 5 ml before being loaded on a
16/60 Superdex 75 (GE Healthcare) equilibrated with 10 mM
Hepes, 300 mM NaCl, pH 7.5 for SEC purification and homoge-
neity analysis, as described previously.
Protein crystallization
Crystallization trials were initiated with the RVFV NP purified
under non-denaturing conditions and TOSV NP purified from IB
using a nano-drop dispenser (Honeybee; Genomic Solutions) in
96-well sitting drop plates (Greiner Bio One). Three commercial
crystallization kits were tested at 20uC: Structure Screen
combination, Stura footprints (Molecular Dimensions Limited),
and Nextal SM1 (Qiagen). For each condition, three drops were
done: 300, 200 or 100 nl were added to 100 nl of the
crystallization solution.
Results
Cloning and expression strategy
The ORFs encoding NP proteins of RVFV, SFSV and TOSV
were cloned in pDONR201 before being re-introduced in two
plasmids for expression as a N-terminal tag fusion, as described in
figure 2. Based on their small size and ability to be purified by
Immobilized Metal Affinity Chromatography (IMAC), only 6His
(3.3 kDa) and TRX-6His (14.6 kDa) tags were selected for the tag
screening although other tags such as 6His/MBP (Maltose Binding
Protein), or 6His/GST (Glutathion S-Transferase) could be
available and compatible with the cloning procedure[33–34].
Nevertheless, the latter tags were not tested because they are much
larger than 6His or TRX-6His and might interfere in the
oligomerization process by steric hindrance. When fused to a
removable 6His tag, the NP proteins can follow two procedures. If
the protein is expressed in the soluble fraction, it can be purified
under non-denaturing conditions. The 6His tagged fusions can
also be expressed as inclusion bodies for subsequent refolding. By
contrast, the TRX-6His was used only for soluble expression for
two reasons. Firstly, the TRX tag is expected to improve protein
solubility. Secondly, if the TRX-6His tag needs to be refolded in a
condition that isn’t compatible with recombinant protein opti-
mum, and vice versa, the presence of the tag would be deleterious
for refolding efficacy. Protein expression was performed in only
one culture condition that was chosen on the conclusions of a
previous report [35]. Briefly, the two main culture parameters
having an impact on soluble expression are the use of rare tRNA
co-expressing strains to improve expression yields, and post-
induction cultures at low temperatures to promote solubility. E. coli
strain carrying a pRARE plasmid (Novagen) and bacterial growth
at 17uC were thus selected.
Protein purification under non-denaturing conditions
For each NP fused with an Nterminus 6His tag, a part of the
recombinant protein can be expressed in its soluble form, as shown
by the amount of protein quantified from the soluble fraction after
IMAC purification (figure 3, data summarized in table1). Among
the 3 NPs, RVFV NP was the only one to be soluble at yields
Production of Phlebovirus Nucleoproteins
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the threshold compatible with downstream crystallogenesis
experiments. Therefore, among the 6His tagged fused proteins,
only RVFV NP was further purified and characterized. When
compared to the amount of the insoluble fraction (data in table 1),
the soluble fraction of NPs corresponds to 1.5% of the overall
expression (3.5 mg in the soluble fraction compared to 240 mg in
the inclusion bodies for RVFV NP), or less for SFSV and TOSV
NPs. By contrast, when fused to the solubilizing TRX-6His tag,
the NPs are 7 to 20-fold more soluble, providing thus enough
material for tag cleavage. Interestingly, the solubility trend
observed with the 6His fusions (RVFV.TOSV.SFSV) is
conserved with the TRX-6His tag.
The removal of the TRX-6His tag was then assessed based on
two criteria. First, the remaining full length TRX-6His-NP can be
quantified and compared to the quantities of the full length
constructs before cleavage. Using this calculation, the best
cleavage efficacy was observed for TOSV NP, for which no
residual full length fusion protein was observed after the TEV
protease cleavage, as shown in figure 4. RVFV NP was also
efficiently recovered since only 13% of the full length was reluctant
to TEV protease cleavage. In contrast with to these two NPs, more
than 90% of the full length TRX-6His-SFSV NP remained
uncleaved after the incubation with TEV protease, resulting in
about 10% cleavage yield. Following the cleavage, the protein
solution is loaded again on a Nickel immobilized column.
Figure 3. Expression levels and IMAC purification results of tagged RVFV and TOSV NPs. Analysis on a Coomassie blue stained SDS Page
gel. S: Soluble fraction of the bacterial lysate; W: Wash step at 50 mM imidazole during the IMAC purification; E: Elution fraction of the IMAC; T: Total
bacterial lysate. The calculated molecular weights of RVFV, SFSV and TOSV NPs without the tags are respectively 27.4, 27.9 and 27.7 kDa. The
calculated molecular weights of the cleavable 6His and TRX-6His tags are respectively 3.3 and 14.6 kDa.
doi:10.1371/journal.pntd.0000936.g003
Table 1. Production results of the Nucleoproteins (NPs) of Rift Valley fever virus (RVFV), Sandly Fever Sicilian virus (SFSV) and
Toscana virus (TOSV).
RVFV NP SFSV NP TosV NP
6His Tag TRX-6His 6His Tag TRX-6His 6His Tag TRX-6His
Native conditions Soluble expression 3.5 mg 26 mg* ,0,5 mg 5 mg* 1 mg 20 mg*
Tag removal N.A 87% N.A ,10% N.A 100%
LMW NP vs all NP 46% 33% N.A N.A N.A 5%
Final quantity of LMW NP 1.4 mg 6 mg N.A N.A N.A 0.9 mg
LMW oligomer Trimer Trimer N.A N.A N.A Trimer
Denaturing conditions Insoluble expression 240 mg 209 mg 234 mg
IB refolding 29% 0% 26%
LMW NP vs all NP 16% N.A 63%
Final quantity of LMW NP 0.7 mg N.A 4m g
LMW oligomer Dimer N.A Trimer
The result at key steps of the process was evaluated. N.A: not applicable, (*): quantities are indicated after the subtraction of the TRX contribution, so figures can be
directly compared, irrespective to the nature of the tag.
doi:10.1371/journal.pntd.0000936.t001
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length fusions, and TEV protease) and separates them from the
untagged protein (cleaved protein of interest) going through the
column. Practically, most of the cleaved TOSV NP was found in
the flow through fraction whereas the 6His tagged proteins and a
small amount of cleaved TOSV NP were trapped on the column
and released during elution (figure 4). The purification of RVFV
NP was not as efficient as for TOSV NP. Indeed, cross
contaminations of full length and cleaved protein can be found
in both flow through and elution pools. However, the cleaved
RVFV NP represents about 90% of the flow through and is
therefore amenable to SEC. For SFSV NP, the cleaved protein
was observed at the elution of the IMAC with the TRX-6His-NP
fusion. Moreover, only non cleaved NP went through the nickel
immobilized column. It was thus concluded that the purification of
SFSV NP failed with the TRX-6His construct and the process was
aborted.
In summary, among the six fusion proteins tested from the
soluble fraction, three constructs yielded amounts and homoge-
neity criteria, as shown in table 1: 6His-RVFV NP, TRX-6His-
RVFV NP and TRX-6His-TOSV NP.
6His-RVFV NP showed a degradation pattern after the IMAC
purification, resulting in four sub-products observed from 26 to
30 kDa (figure 3), whereas the expected size of the NP with the
6His Tag is 31 kDa. The oligomerization of the sub-products was
then analyzed by SEC (figure 5, panel A). Based on the calibration
curve, the main part of the 6His-RVFV NP eluted at 94 kDa that
could correspond to a trimer of 6His-NP (theoretical MW:
93 kDa). A larger oligomer over 300 kDa was also observed. The
oligomerization of the NP is independent to the protein
degradation since the four cleaved products are almost equally
distributed along the chromatogram (figure 5, panel A). Therefore,
although the criteria in homogeneity and quantity were reached
(see Table 1), crystallization trials were not launched because of
protein degradation.
SEC was also performed for the NP of both RVFV and TOSV
after release of the TRX-6His tag. RVFV NP mainly eluted at
93 kDa (figure 5, panel B) following the same trend as that of 6His-
RVFV NP. In order to compare the oligomerization state of the
RVFV NP in this protocol to a previous study [20], several
fractions from 300 to 30 kDa were treated with or without
glutaraldehyde and analyzed on Coomassie blue stained SDS Page
(figure 6). The cross-linking with glutaraldehyde resulted in three
major populations (monomers (1NP), dimers (2NP) and timers
(3NP)) as well as to a lower extent tetramers and high molecular
complexes on the top of the gel. The amounts of monomers,
dimers, trimers and tetramers remained almost unchanged along
the chromatogram. By contrast, crosslinked HMW complexes
could be observed in the fractions that were collected at low
elution volumes. Unlike the corresponding 6His tagged NP, the
protein was pure and not degradated as judged by Coomassie Blue
stained SDS Page (Figure 6). Fractions corresponding to the major
peak were pooled and the so-called LMW NP gathered 33% of the
injected NP. The behavior of TOSV NP after the TRX-6His tag
cleavage was different: most of the protein eluted at 193 kDa and
the LMW NP corresponds to about 5%, leading to less than 1 mg
of protein (table 1). Nevertheless, the protein eluting at 193 kDa
was pooled and concentrated for crystallogenesis experiments.
Purification under denaturing conditions and refolding of
IB
More than 200 mg of each of the 6His-NP constructs were
expressed as inclusions bodies (table 1). Since the recombinant
proteins were highly expressed, two standard washes of the
inclusion bodies were sufficient to recover NPs that are more than
90% pure, as shown in the total fraction of the refolded NPs
(figure 7). Therefore, neither additional purification step nor
optimized washes were needed before refolding. The theoretical
isoelectric point (pI) for RVFV, SFSV and TOSV are respectively
9.8, 10.1 and 9.9. In order to refold 6His-NPs at a pH distant to
the protein pI, it was decided to refold at a low pH and sodium
acetate at pH 4.5 was selected. A first analysis of the protein
refolding efficacy was performed by comparing the total amount of
6His-NP to be refolded (e.g. 30 mg for each NP) with the soluble
and filtrated fraction after overnight dilution in the refolding
buffer. Quantitative data (table 1) were obtained by comparing
OD280 nm in the total and soluble fractions. Qualitative data
(protein purity, and degradation) were evaluated using Coomassie
Figure 4. TRX-6His tag removal by TEV protease analysed on Coomassie blue stained SDS Page gel. BC: Before cleavage; AF: After
cleavage; FT: Flow Through fraction of the IMAC; W: Wash step at 50 mM imidazole during the IMAC purification; E: Elution fraction of the IMAC; FL
NP: Full length TRX-6His construct; TEV Pro: TEV protease; MW: Molecular weight marker, same ladder as figure 3.
doi:10.1371/journal.pntd.0000936.g004
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TOSV 6His-NP were recovered in the soluble fraction whereas
the corresponding SFSV construct was completely insoluble after
refolding.
The oligomerization states of RVFV 6His-NP after refolding
was different to the ones observed for the soluble corresponding
NPs. Most of the protein eluted at 134 kDa (4,3 molecules of 6His-
NP) during the SEC. A minor peak at 56 kDa (1,8 6His-NP) was
also observed (figure 5). This latter population corresponds to 16%
of the injected protein, leading to less than 1 mg of protein from
the 30 mg used for refolding. The chromatogram of the refolded
TOSV 6His-NP shows a homogeneous protein with peaks at
Figure 6. SEC fractions of RVFV NP with or without glutaraldehyde. Analysis on Coomassie blue stained SDS Page gel.
doi:10.1371/journal.pntd.0000936.g006
Figure 5. SEC chromatograms at OD280 nm for RVFV and TOSV NPs produced in different conditions. The molecular weights have been
extrapolated from the elution volumes using a calibration curve. Panel A corresponds to SEC chromatogram of 6His constructs purified in non-
denaturing conditions, Panel B: TRX-6His constructs in non-denaturing conditions, Panel C: 6His constructs after refolding.
doi:10.1371/journal.pntd.0000936.g005
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6His-NP). The NP eluting at 97 kDa corresponds to 63% of the
injected protein (4 mg). The two protein pools corresponding to
the peaks 97 and 33 kDa were separately used for crystallogenesis
trials.
Protein crystallization
RVFV NP and TOSV NPs obtained from the non-denaturing
production pipeline after TRX-6His removal, as well as the two
pools (97 kDa and 33 kDa) of the refolded 6His-TOSV NP were
finally concentrated in the SEC buffer up to 6.6 mg/ml, 6.3 mg/
ml, 7.4 mg/ml and 3 mg/ml respectively. From the commercial
kits, several crystal hits were obtained for RVFV NP (figure 8,
panel A), and one condition lead to sea urchin crystals of the
97 kDa MW TOSV NP (figure 8, panel B).
Discussion
The initial objective of this study was to produce and purify
phlebovirus NPs for structural studies. According to the previously
reported studies, NPs were described as insoluble [23] or HMW
complexes [22]. Oppositely to the latter strategy whose goal was to
identify the viral organization of Rift Valley fever virus at the
macromolecular level, our aim was to find a procedure to produce
soluble and LMW NPs. Therefore, we decided to adopt a naive
approach testing in parallel several methods and evaluate them on
the basis of protein solubility and production of LMW NPs. With
these two evaluation criteria, we devised an easy ‘‘Go/No Go’’
pipeline (figure 2) that enables the comparison of the methods and
the selection of the best one, in order to reach the required amount
of homogeneous NP for crystallogenesis. For several reasons, it was
decided to take advantage of the natural diversity within the viral
genus. Firstly, screening several homologues can be considered as
an additional experimental variable. It has already been
demonstrated that it can improve the success rate to find at least
one sequence suitable for structural studies [36]. Secondly, the
cumulative data of several proteins could benchmark the protocol
described in figure 2. Finally, it could be of interest to see if
phlebovirus NPs, share preliminary structural features such as
oligomerization. Three phleboviruses belonging to distinct phylo-
genic clusters based on NP sequences [37] were therefore selected,
the pairwise sequence identities of the NPs being 50% id. between
RVFV and TOSV, 47% id. between RVFV and SFSV and 40%
id. between TOSV and SFSV.
Among these three NPs, SFSV NP was the most reluctant to all
strategies. Either the protein with a 6His tag is poorly soluble, or it
cannot be refolded easily. When expressed in fusion with the
TRX-6His sequence, the solubility issue is overcome but the fusion
protein was almost refractory to TEV protease cleavage.
Moreover, the cleaved and uncleaved forms co-eluted together
on IMAC with no rational on the presence/absence of the 6His
sequence. Altogether, these data suggest that even if the TRX-
6His solubilizes the SFSV NP, the fusion protein organizes in
soluble aggregates, as already observed with MBP when it is fused
Figure 7. Refolding efficacy for the three NPs analysed on Coomassie blue stained SDS Page gel. BR: Before refolding; AR: soluble and
filtrated fraction obtained after refolding.
doi:10.1371/journal.pntd.0000936.g007
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RVFV and TOSV were soluble and easier to handle. However,
sequence analysis for solubility in E. coli [39] did not allow
predicting of the untracktability of SFSV compared to the two
other NPs. Again, it suggests that the success rate of producing a
class of proteins depends on the number of homologues tested
experimentally. Alternatively, specific point mutations of poorly
conserved amino acids between SFSV and the two others NPS
might constitute a successful strategy to obtain soluble or stable
SFSV NP. Such a study might help to point out critical residues
like prolines or cysteines that can be involved in recombinant
protein folding/misfolding.
TOSV NP was soluble in both 6His and TRX-6His constructs
but the latter tag improved solubility about 20-fold. The tag was
cleaved and the SEC chromatogram revealed two NP populations
that could correspond to hexameric and trimeric complexes
(figure 5, panel B). Surprisingly, the oligomerization states shifted
to putative trimers and monomers (panel C) from the purification
under denaturing conditions followed by refolding. A much more
striking difference was observed for the RVFV NP. Both
constructs (6His-NP and NP) from the non-denaturing pipeline
eluted mainly as putative trimers (figure 5, panels A and B),
whereas 6His-NP after refolding formed putative monomers,
dimers and tetramers (panel C). This ‘‘2X’’ multimerization is in
agreement with results obtained for refolded RVFV NP that lead
to the structure determination of a NP dimer [26] but it differs
from the ‘‘3X’’ multimerization of native and refolded TOSV NP
and native RVFV NP. Our data suggest that the choice of the
purification procedure (i.e., denaturing vs non-denaturing condi-
tions) has an impact on the oligomerization state going through
two divergent directions and at this stage, we were not able to
claim if the difference was due to a refolding artifact or an
equilibrium between the two forms.
In a previous study, it was demonstrated that the RVFV NP can
dimerize through an interaction involving the N-terminal domain
[20]. When cross linking RVFV NP with glutaraldehyde, we did
confirm that the protein expressed in E. coli is able to dimerize but
also to produce tri- and tetramers (figure 6). These latter oligomers
almost disappeared in the HMW NP (.300 kDa), suggesting that
HMW could behave like RNPs purified from infected Vero cells
[20]. For the lower molecular weight complexes, the cross linking
with glutaraldehyde resulted in the formation of a ladder that is
probably due to a non specific reaction. Since SEC chromato-
grams of the soluble 6His-RVFV NP and RVFV-NP are almost
superimposable, the 6His tag was not responsible for the
oligomerization differences.
Two NP pools crystallized (figure 8), one from the non-
denaturing pathway (RVFV NP) and one from the refolding one
(TOSV NP). In both cases, crystals were obtained with trimeric
NPs. These results raise the importance to investigate the
production under not only the native conditions but also the
denaturing conditions for at least two raisons. Firstly, in contrast
with to the soluble fraction of RVFV 6His-NP, refolded 6His-NP
remained not degraded, even after refolding. It can be noticed that
the degradation of the 6His-NP, when processed in non-denaturing
conditions, occurred at an early stage of the production (figure 3),
probably during the culture growth or bacterial lysis, whereas the
NPs produced as IB are prevented from bacterial proteolysis.
Secondly, the putative trimer of TOSV NP that crystallized was
obtained in higher amounts after refolding than in the soluble
fraction that majorly lead to a heterogeneous oligomer preparation.
Nevertheless, refolding from solubilized inclusion bodies met some
limits in the purification of NP. When SFSV NP is not soluble and
homogeneous even with the TRX tag, the refolding strategy also
failed. Moreover, the renatured RVFV NP produced multimers
that aredifferent from RVFV and TOSV NPspurified under native
conditions, in agreement with a previous study [26]. Although it
remains unclear if the differences in the oligomerization states
highlight a difference in protein folding, the structure of a
phlebovirus NP as a trimer would certainly help understanding
the oligomerization determinants of phlebovirus NPs.
Conclusion
The standard pipeline investigating conditions under both
denaturing and non-denaturing conditions was proven to be
efficient and could be applied to any recombinant protein. With
no need of further refinement, two out of the three phlebovirus
NPs were produced and purified in suitable amount and quality
for crystallogenesis. Trimeric forms of RVFV and TOSV NPs
yielded crystals. This result is a starting point for structural studies
aiming at the elucidation of the RNA encapsidation mechanism, a
targetable step for antiviral research [40].
Figure 8. Crystal hits of RVFV and TOSV NP from the commercial kits. Panel A: RVFV NP in 30% PEG 4000, 0.2 M imidazole malate pH 6 (from
Stura Footprint Screen, Molecular Dimensions). Panel B: TOSV NP in 33% PEG 600 0.2 M imidazole malate pH 5.5 (from Stura Footprint Screen,
Molecular Dimensions).
doi:10.1371/journal.pntd.0000936.g008
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